Zynerba Pharmaceuticals Stock Forecast, Price & News

-0.11 (-1.97 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.20 million shs
Average Volume3.69 million shs
Market Capitalization$225.65 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Zynerba Pharmaceuticals logo

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.22 out of 5 stars

Medical Sector

943rd out of 2,097 stocks

Pharmaceutical Preparations Industry

457th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

Is Zynerba Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zynerba Pharmaceuticals stock.
View analyst ratings for Zynerba Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Zynerba Pharmaceuticals?

Wall Street analysts have given Zynerba Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zynerba Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 2,330,000 shares, a decline of 35.5% from the May 13th total of 3,610,000 shares. Based on an average daily volume of 1,760,000 shares, the short-interest ratio is currently 1.3 days. Currently, 5.8% of the company's stock are sold short.
View Zynerba Pharmaceuticals' Short Interest

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Zynerba Pharmaceuticals

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.20) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.05.
View Zynerba Pharmaceuticals' earnings history

How has Zynerba Pharmaceuticals' stock price been impacted by Coronavirus?

Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZYNE stock has increased by 40.6% and is now trading at $5.47.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZYNE?

6 brokerages have issued 12 month target prices for Zynerba Pharmaceuticals' stock. Their forecasts range from $7.25 to $26.00. On average, they expect Zynerba Pharmaceuticals' share price to reach $13.65 in the next twelve months. This suggests a possible upside of 149.5% from the stock's current price.
View analysts' price targets for Zynerba Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the following people:
  • Mr. Armando Anido MBA, Chairman & CEO (Age 63, Pay $902.08k)
  • Ms. Terri B. Sebree, Pres (Age 63, Pay $686.79k)
  • Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 57, Pay $582.82k)
  • Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 64)
  • Dr. Joseph Palumbo, Chief Medical Officer

Who are some of Zynerba Pharmaceuticals' key competitors?

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AdvisorShares Investments LLC (3.73%), Davy Global Fund Management Ltd (1.75%), BlackRock Inc. (1.44%), Penserra Capital Management LLC (0.87%), D. E. Shaw & Co. Inc. (0.74%) and Mirae Asset Global Investments Co. Ltd. (0.71%).
View institutional ownership trends for Zynerba Pharmaceuticals

Which major investors are selling Zynerba Pharmaceuticals stock?

ZYNE stock was sold by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., JPMorgan Chase & Co., and Northern Trust Corp.
View insider buying and selling activity for Zynerba Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was bought by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Davy Global Fund Management Ltd, D. E. Shaw & Co. Inc., Penserra Capital Management LLC, BlackRock Inc., Geode Capital Management LLC, HRT Financial LP, and Goldman Sachs Group Inc..
View insider buying and selling activity for Zynerba Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $5.47.

How much money does Zynerba Pharmaceuticals make?

Zynerba Pharmaceuticals has a market capitalization of $225.65 million and generates $90,000.00 in revenue each year. The company earns $-51,340,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does Zynerba Pharmaceuticals have?

Zynerba Pharmaceuticals employs 26 workers across the globe.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is

Where are Zynerba Pharmaceuticals' headquarters?

Zynerba Pharmaceuticals is headquartered at 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.